Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News

Medically suspect criterion can determine bariatric surgery coverage
- Author:
- Mitchel L. Zoler, PhD
Some health insurers require certain patients seeking bariatric surgery to first-fail treatment with three...
News

Bariatric surgery cuts insulin needs in type 1 diabetes with severe obesity
- Author:
- Mitchel L. Zoler, PhD
By substantially cutting weight and thereby boosting insulin sensitivity bariatric surgery helps patients with...
News
Bariatric surgery tied to fewer HFpEF hospitalizations
- Author:
- Mitchel L. Zoler, PhD
Data from the U.S. National Inpatient Sample show a significant link between prior bariatric surgery and fewer...
News

‘Twincretin’ meets primary endpoints in five pivotal diabetes trials
- Author:
- Mitchel L. Zoler, PhD
Lilly’s novel “twincretin” tirzepatide met its primary, A1c-lowering endpoint in five pivotal RCTs of patients...
News

Mavacamten boosts quality of life in patients with hypertrophic cardiomyopathy
- Author:
- Mitchel L. Zoler, PhD
Oral mavacamten significantly improved quality of life in a prespecified secondary endpoint from the EXPLORER-HCM pivotal trial.
News

Dapagliflozin’s cost-effectiveness ‘intermediate’ for HFrEF
- Author:
- Mitchel L. Zoler, PhD
Results from DAPA-HF and U.S. pricing show dapagliflozin costs about $84,000/quality-adjusted life year, which...
News
Prediabetes linked to higher CVD and CKD rates
- Author:
- Mitchel L. Zoler, PhD
Data from more than 330,000 U.K. adults show that an A1c of 5.7%-6.4% links with higher rates of incident CKD and CVD events.
News

Rivaroxaban cut recurrent limb events in VOYAGER-PAD
- Author:
- Mitchel L. Zoler, PhD
Analysis of both first and subsequent major adverse limb events in the VOYAGER-PAD trial documents ongoing...
News

Sotagliflozin’s HFpEF benefit confirmed by new analyses
- Author:
- Mitchel L. Zoler, PhD
A meta-analysis of two pivotal trials for the SGLT1/2 inhibitor sotagliflozin prospectively documents a HFpEF...
News

FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD
- Author:
- Mitchel L. Zoler, PhD
A prespecified, exploratory analysis from the FIDELIO-DKD trial showed that the nonsteroidal MRA finerenone...
News

Ultrasound renal denervation drops BP in patients on triple therapy
- Author:
- Mitchel L. Zoler, PhD
In a sham-controlled, randomized study, renal denervation with ultrasound cut systolic blood pressure by a...
News

PARADISE-MI: Sacubitril/valsartan can’t beat ramipril in patients with acute MI
- Author:
- Mitchel L. Zoler, PhD
When treating patients with no history of heart failure within days of an acute myocardial infarction,...
News
FDA blazes path for ‘real-world’ evidence as proof of efficacy
- Author:
- Mitchel L. Zoler, PhD
FDA leaders must finalize guidance this year on submitting real-world observational evidence for regulatory decisions on drug and device efficacy...
News
Finerenone scores second pivotal-trial success in patients with diabetic kidney disease
- Author:
- Mitchel L. Zoler, PhD
Top-line results from FIGARO-DKD, the second pivotal trial for finerenone in patients with type 2 diabetes and...
News
Two treatments show early promise for hypothalamic obesity
- Author:
- Mitchel L. Zoler, PhD
Both the ADHD drug dextroamphetamine, and a compound of a novel monoamine reuptake inhibitor and a beta-blocker...